Japanese drugmaker Takeda has released the results of an internal probe over an inappropriate ad for blood pressure medicine BIopress, which, according to the Wall Street Journal, utilized an incorrect chart and “raised suggestions of manipulated trial data.” The company denies wrongdoing. The report is only available in Japanese, however, and WSJ reports that questions regarding an English version have gone unanswered, raising questions on whether the company is trying to be transparent, or merely to appear transparent.
Takeda releases internal probe over bad ad
An internal probe for a controversial ad for hypertension drug Blopress was released by Takeda, but the report is in Japanese.